New York investment fund Platinum-Montaur Life Sciences LLC exercised Series W warrants to purchase 6 million shares of common stock in Navidea Biopharmaceuticals Inc., of Dublin, Ohio
By Marie Powers | BioWorld Today | Friday, December 21, 2012
Existing investors Edmond de Rothschild Investment Partners, Domain Associates, Quaker Partners, Aurora Funds and Caxton Advantage Life Sciences Fund also took part
By Randy Osborne | BioWorld Today | Thursday, December 20, 2012
According to Brinson Patrick Securities Corp., use of ATM offerings by life sciences companies reached a record high in the third quarter...Part of the year-over-year increase is due to a general uptick in the amount of capital that life sciences companies have raised
Medicago Inc., of Quebec City, and Folia Biotech Inc., also of Quebec, received C$415,000 (US$421,172) in financial support from the Quebec government and municipality of Quebec City to fund a feasibility study for a project known as BioProduction21, part of the Quebec Region's Life Science ACCORD Cluster
According to Brinson Patrick Securities Corp., use of ATM offerings by life sciences companies reached a record high in the third quarter...Part of the year-over-year increase is due to a general uptick in the amount of capital that life sciences companies have raised
By Brian Orelli | BioWorld Insight | Monday, December 17, 2012
They completely understand what DeCode is about, and what they're trying to do." – Terry McGuire, Polaris Venture Partners "Life sciences is what has provided most of the returns at Sofinnova over a long period of time, across all of the funds." – Antoine Papiernik, managing partner, Sofinnova Partners
For the first time, Paris-based Sofinnova is focusing exclusively on life sciences, having previously invested more than a quarter of its capital, including its €260 million sixth fund, in IT...Life sciences is what has provided most of the returns at Sofinnova over a long period of time, across all of the funds," managing partner, Antoine Papiernik, told BioWorld International
For the first time, Paris-based Sofinnova is focusing exclusively on life sciences, having previously invested more than a quarter of its capital, including its €260 million sixth fund, in IT...Life sciences is what has provided most of the returns at Sofinnova over a long period of time, across all of the funds," managing partner, Antoine Papiernik, told BioWorld Today
By Cormac Sheridan | BioWorld Today | Wednesday, December 12, 2012
Writing in the review, the so-called "Life Sciences Champions" appointed to monitor implementation of the strategy said there are some early success stories, such as the £160 million Biomedical Catalyst, a public fund set up to help advance academic projects across the valley of death by providing support to shape them into programs that can attract private investment...Steve Bates, BIA CEO said all the projects and progress with the Strategy for Life Sciences are welcome, but that "financing
By Nuala Moran | BioWorld International | Wednesday, December 12, 2012
For the first time, Paris-based Sofinnova is focusing exclusively on life sciences, having previously invested more than a quarter of its capital, including its €260 million sixth fund, in IT...Life sciences is what has provided most of the returns at Sofinnova over a long period of time, across all of the funds," managing partner, Antoine Papiernik, told BioWorld International
By Cormac Sheridan | BioWorld International | Wednesday, December 12, 2012
ProMetic Life Sciences Inc., of Laval, Quebec, said it achieved the first milestone related to the advancement of a plasma-derived biopharmaceutical product targeting a rare medical condition in partnership with Hematech Biotherapeutics Inc., of Taipei, Taiwan
Isotechnika Pharma Inc., of Edmonton, Alberta, said a partial award has been issued in the company's ICC arbitration regarding its right to terminate the development, distribution and license agreement with Iljin Life Sciences Co
Ltd., closed a $7M first round of financing 11/1/12 Kiadis Pharma BV Amsterdam, the Netherlands €10 ($12.8) Kiadis raised $12.8M in a round led by LSP (Life Sciences Partners), and supported by a large investment from DFJ-Esprit
The TVM Life Science Ventures VII, for example, has C$150 million that it will use to invest primarily on early stage drug development and life sciences company opportunities in Quebec. (See BioWorld Insight, June 11, 2012.) Eli Lilly and Co
By Peter Winter | BioWorld Insight | Monday, December 3, 2012
New York investment fund Platinum-Montaur Life Sciences LLC exercised Series W warrants to purchase 6 million shares of common stock in Navidea Biopharmaceuticals Inc., of Dublin, Ohio